From Cost per Gigabase to Clinical Impact: Rethinking Genomics Value

For years, progress in genomics has been measured by one metric: cost per gigabase. And by that standard, the industry has been remarkably successful.

But as genomics moves into the clinic, that metric is no longer enough.

Health systems do not operate on sequencing output—they operate on decisions, workflows, and patient outcomes. The real question is no longer how cheaply data can be generated, but how effectively it can be translated into clinical action.

This shift is already underway. While applications such as cancer diagnostics and rare disease analysis are gaining traction, broader clinical adoption remains constrained—not by sequencing technology, but by systems.

Challenges persist across interpretation, standardization, and integration. Variant classification remains complex. Clinical workflows are not yet optimized for genomic data. Infrastructure and bioinformatics continue to carry significant cost and complexity.

As Hal Paz recently noted, “systems readiness is not the same as technological readiness.”

Taken together, the transition of genomics into the clinic is not a technology upgrade—it is a systems transformation. One that spans data interpretation, clinical workflows, infrastructure, and regulation.

For investors and operators alike, the implication is clear:
the next wave of value in genomics will come not from generating more data—but from making that data usable in real-world care.

For a deeper analysis, including bottlenecks in clinical adoption and where AI may unlock progress, read the full discussion in our newsletter.